-transparent.png){kind=logo}
(+)-N-Propargyl-1-aminoindan (rasagiline) and a series of derivatives have been synthesized and screened for monoamine oxidase inhibitory activity. Rasagiline and several analogues were found be highly selective and potent inhibitors of the B form of the enzyme in contrast to the levorotatory enantiomer which was not active. The results indicate that rasagiline has potential for the treatment of Parkinson's Disease. This compound is currently under development for that indication.
Related Publications
J Sterling, and
A Veinberg, and
D Lerner, and
W Goldenberg, and
R Levy, and
M Youdim, and
J Finberg
January 2001,
British journal of pharmacology,
J Sterling, and
A Veinberg, and
D Lerner, and
W Goldenberg, and
R Levy, and
M Youdim, and
J Finberg
January 1998,
Journal of neural transmission. Supplementum,
J Sterling, and
A Veinberg, and
D Lerner, and
W Goldenberg, and
R Levy, and
M Youdim, and
J Finberg
January 1999,
Advances in neurology,
J Sterling, and
A Veinberg, and
D Lerner, and
W Goldenberg, and
R Levy, and
M Youdim, and
J Finberg
January 1998,
Journal of neural transmission. Supplementum,
J Sterling, and
A Veinberg, and
D Lerner, and
W Goldenberg, and
R Levy, and
M Youdim, and
J Finberg
November 2019,
Bioorganic chemistry,
J Sterling, and
A Veinberg, and
D Lerner, and
W Goldenberg, and
R Levy, and
M Youdim, and
J Finberg
February 2010,
Bioorganic & medicinal chemistry,
J Sterling, and
A Veinberg, and
D Lerner, and
W Goldenberg, and
R Levy, and
M Youdim, and
J Finberg
August 2009,
Neurotoxicity research,
J Sterling, and
A Veinberg, and
D Lerner, and
W Goldenberg, and
R Levy, and
M Youdim, and
J Finberg
November 1995,
Journal of medicinal chemistry,
J Sterling, and
A Veinberg, and
D Lerner, and
W Goldenberg, and
R Levy, and
M Youdim, and
J Finberg
February 2018,
European journal of medicinal chemistry,
J Sterling, and
A Veinberg, and
D Lerner, and
W Goldenberg, and
R Levy, and
M Youdim, and
J Finberg
April 2018,
Bioorganic chemistry,
